Live Micron Technology Inc Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Vicapsys Life Sciences, Inc.

Get SEC filing alerts via email and in your feed for Vicapsys Life Sciences, Inc.

VICP

Vicapsys Life Sciences, Inc.

About Vicapsys Life Sciences, Inc.

Vicapsys Life Sciences Inc. develops proprietary cellular therapies and encapsulation technologies for treating Type 1 Diabetes and related conditions. Its VICAPSYN line targets transplantation and stem-cell applications, aiming to prevent fibrosis and improve cell survival. The company holds licensing agreements, focuses on preclinical research, and operates in the regenerative medicine and biopharmaceutical markets, emphasizing innovation, intellectual property, and regulatory compliance.
This description was generated via AI from an annual report. Updated 9 months ago.

Latest SEC Filings from Vicapsys Life Sciences, Inc.

1
1
Vicapsys Life Sciences, Inc. Vicapsys Life Sciences Reports No Revenue and Increased Losses for Q3 and Nine Months Ended September 30, 2024

Via official filing (AI summary) | over 1 year ago | 0 comments

2
1
Vicapsys Life Sciences, Inc. Vicapsys Life Sciences Reports No Revenue and Increased Losses for Six Months Ended June 30, 2024

Via official filing (AI summary) | over 1 year ago | 0 comments

3
1
Vicapsys Life Sciences, Inc. Vicapsys Life Sciences Reports No Revenue and Increased Net Loss in Q1 2024

Via official filing (AI summary) | over 1 year ago | 0 comments